Insider Selling: Amicus Therapeutics, Inc. (FOLD) CEO Sells 18,970 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 18,970 shares of the firm’s stock in a transaction dated Friday, December 29th. The stock was sold at an average price of $14.75, for a total transaction of $279,807.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $15.51 on Thursday. Amicus Therapeutics, Inc. has a 12 month low of $5.07 and a 12 month high of $16.60. The company has a quick ratio of 6.22, a current ratio of 6.32 and a debt-to-equity ratio of 0.39. The firm has a market cap of $2,580.00, a PE ratio of -8.48 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million during the quarter, compared to analyst estimates of $9.02 million. During the same quarter last year, the firm earned ($0.33) EPS. Amicus Therapeutics’s revenue for the quarter was up 419.0% compared to the same quarter last year. equities analysts expect that Amicus Therapeutics, Inc. will post -1.56 earnings per share for the current fiscal year.

A number of analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, December 19th. Leerink Swann restated a “buy” rating and set a $20.00 target price (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Robert W. Baird restated an “outperform” rating and set a $16.00 target price on shares of Amicus Therapeutics in a research note on Monday, September 25th. Bank of America raised their target price on shares of Amicus Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday, October 4th. Finally, Goldman Sachs Group restated a “neutral” rating and set a $17.00 target price on shares of Amicus Therapeutics in a research note on Friday, October 6th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $18.31.

Several large investors have recently modified their holdings of the company. Sage Capital Advisors llc acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $154,000. GSA Capital Partners LLP acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $309,000. Iguana Healthcare Management LLC acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $905,000. Sterling Capital Management LLC acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $218,000. Finally, Neuberger Berman Group LLC acquired a new position in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $196,000.

ILLEGAL ACTIVITY WARNING: “Insider Selling: Amicus Therapeutics, Inc. (FOLD) CEO Sells 18,970 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another domain, it was copied illegally and republished in violation of international copyright & trademark laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2018/01/11/john-f-crowley-sells-18970-shares-of-amicus-therapeutics-inc-fold-stock.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply